Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: A meta-analysis of 12 randomized controlled trials

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wang, Juan ^a   Zou, Ze Hong ^a   Xia, Hong Lin ^a   He, Jian Xing ^a   Zhong, Nan Shan ^a   Tao, Ai Lin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOCETAXEL; EMEPEPIMUT S; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELATONIN; MITOMYCIN C; MONOCLONAL ANTIBODY; MYCOBACTERIUM VACCINE; NAVELBINE; PLATINUM COMPLEX; RECOMBINANT INTERLEUKIN 2; SRL 172; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FOLLOW UP; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; IMMUNOTHERAPY; LUNG TUMOR; METHODOLOGY; PATHOLOGY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM STAGING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY;

EID: 84863299032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032695     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, et al. (2009) Vaccines for the treatment of non-small-cell lung cancer: a renewed anticancer strategy. Oncologist 14: 909-920.
3. Yasumoto K, Hanagiri T, Takenoyama M, (2009) Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 57: 449-457.
4. Kakimi K, Nakajima J, Wada H, (2009) Active specific immunotherapy and cell-transfer therapy for the treatment of non-small-cell lung cancer. Lung Cancer 65: 1-8.
5. Palmer M, Parker J, Modi S, Butts C, Smylie M, et al. (2001) Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3: 49-57.
6. Gadgeel SM, (2011) The optimal chemotherapy for stage III non-small cell lung cancer patients. Curr Oncol Rep 13: 272-279.
7. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, et al. (2010) Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 28: 620-627.
8. Holt GE, Podack ER, Raez LE, (2011) Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 8: 43-54.
9. Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, et al. (2004) Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 2800-2807.
10. Morgensztern D, Goodgame B, Govindan R, (2010) Vaccines and immunotherapy for non-small-cell lung cancer. J Thorac Oncol 5: S463-465.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12.
13. Rao B, Han M, Wang L, Gao X, Huang J, et al. (2011) Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med 9: 17-27.
14. Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, et al. (1999) Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 20: 448-452.
15. Wu S, Keresztes RS, (2011) Antiangiogenic agents for the treatment of non-small-cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest 29: 460-471.
16. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, et al. (1994) A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small-cell lung cancer. Tumori 80: 464-467.
17. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A, (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26: 53-77.
18. Cox DR, (1972) Regression models and life-tables. J Royal Statistical Soc B (Methodological) B34: 187-220.
19. Thatcher N, Heighway J, (2010) Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small-cell lung cancer. Oncologist 15: 1034-1042.
20. Higgins J, Thompson S, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
21. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catala Ferrer M, Bravo I, et al. (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26: 1452-1458.
22. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, et al. (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23: 6674-6681.
23. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, et al. (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15: 19-27.
24. Lasalvia-Prisco E, Garcia-Giralt E, Vazquez J, Aghazarian M, Lasalvia-Galante E, et al. (2008) Randomized phase II clinical trial of chemo-immunotherapy in advanced non-small-cell lung cancer. Biologics 2: 555-561.
25. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, et al. (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28: 911-917.
26. O'Brien ME, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, et al. (2004) SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 15: 906-914.
27. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531.
28. Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M, et al. (2011) Chemotherapy with or without low-dose interleukin-2 in advanced non-small-cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol 39: 1011-1017.
29. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, et al. (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19: 362-369.
30. Wu C, Jiang J, Shi L, Xu N, (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small-cell lung cancer. Anticancer Res 28: 3997-4002.
31. Zhong R, Teng J, Han B, Zhong H, (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60: 1497-1502.
32. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
33. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D, (2000) Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53: 676-680.
34. Sun X, Briel M, Walter SD, Guyatt GH, (2010) Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 340: c117.
35. Perroud MW Jr, Honma HN, Barbeiro AS, Gilli SC, Almeida MT, et al. (2011) Mature autologous dendritic cell vaccines in advanced non-small-cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res 30: 65-72.
36. Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, et al. (2009) Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non-small-cell lung cancer (NSCLC) patients. Cancer Gene Ther 16: 620-624.
37. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, et al. (2006) Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13: 555-562.
38. Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, et al. (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14: 840-846.
39. Strand L, Morley P, Cipolle R, Ramsey R, Lamsam G, (1990) Drug-related problems: their structure and function. Ann Pharmacother 24: 1093-1097.
40. Bettauer RH, (2011) Systematic review of chimpanzee use in monoclonal antibody research and drug development: 1981-2010. ALTEX 28: 103-116.
41. Limb SL, Starke PR, Lee CE, Chowdhury BA, (2007) Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 120: 1378-1381.
42. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, et al. (2007) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120: 1373-1377.
43. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, et al. (2005) Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23: 4999-5006.